Immutep CEO Marc Voigt talks to Finance News Network after the first patient was recently dosed in Immutep Limited's first in human trial of IMP761. IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases. Safety data is anticipated by year-end and pharmacokinetics and pharmacodynamics data in first half CY2025. #LAG3 #AutoimmuneDisease #clinicaltrials https://lnkd.in/grzEMuWf
Immutep Limited’s Post
More Relevant Posts
-
Exciting findings from EULAR 2024 Annual Meeting reveal that Canakinumab offers a groundbreaking treatment approach for systemic juvenile idiopathic arthritis (sJIA) patients. This study shows sustained disease control without glucocorticoids, with fever controlled after just one injection. Dr. Horneff's research paves the way for steroid-free management of sJIA. Read more for insights on this promising first-line monotherapy. #rheumatology #sJIA #Canakinum
-
MSAT Scientist I Personalized Medicine I Ai/ML| hiPSCs stem cells | Analytics & QC | cGMP | Cell & Gene Therapy | CAR-T ♋I CAR-T | ImmunoTherapy | Gene editing CRISPR🧬✂️ #CAR-T🔬🦠🩸🫁🫀|
A fascinating new article explores the comparative efficiency of B-cell depletion in tissues following CAR-T therapy versus Rituximab, offering insights into why Rituximab may be less effective in treating functional autoimmune diseases. https://lnkd.in/gx8Nhc-5
-
-
The published article "Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis" from Shizuya Yamashita, Manfredi Rizzo, and colleagues is fully available here 👉 https://lnkd.in/gqAJaT8P #PPARα #SPPARMα #pemafibrate #triglycerides #dyslipidemia
-
-
Literature Highlights are an excellent way to stay up to date on the latest publications in axSpA. Download our highlights slide deck today on the Immune-mediated Inflammatory Disease forum to gain valuable insights for your clinical practice! https://lnkd.in/eh83F4v5 #IMIDforum #axSpA #rheumatology #secukinumab #JAKi
-
-
Literature Highlights are an excellent way to stay up to date on the latest publications in axSpA. Download our highlights slide deck today on the Immune-mediated Inflammatory Disease forum to gain valuable insights for your clinical practice! https://lnkd.in/e9jk5YT4 #IMIDforum #axSpA #rheumatology #secukinumab #JAKi
-
-
🧬 Get to know the possibilities offered by #qPCR in the development of #therapeutic #oligonucleotides to address rare diseases in the blog post we have prepared.⬇️ Keep reading 👁️ 📝 https://swki.me/W2yHnGws #fundedbyCDTI
-
-
Cytokeratin-18 was a more sensitive marker of drug-induced liver disease than ALT, miR-122 or GLDH and has potential significant utility in the early identification of #DILI in trials and clinical practice. #OpenAccess https://lnkd.in/eqDBZ373
-
TSLP and TL1A are so hot right now! Well in Inflammatory Disease research they are...so if this floats your boat, you should check out the recording our recent webinar with BPS Bioscience Inc. on Deciphering the Roles of TSLP, TL1A, and OX40 Signaling Pathways in Inflammatory Diseases Contact us for more information on BPS Bioscience's products for Autoimmunity. https://lnkd.in/g6KZRkGd #ibd #inflammatoryboweldisease #autoimmunity #inflammatorydiseases #chrohnsdisease
-
-
Literature Highlights are an excellent way to stay up to date on the latest publications in axSpA. Download our highlights slide deck today on the Immune-mediated Inflammatory Disease forum to gain valuable insights for your clinical practice! https://ow.ly/ZwXz50RvEvg #IMIDforum #axSpA #rheumatology #secukinumab #JAKi
-
-
The #IL-6 (#Interleukin6) target is a pro-inflammatory cytokine that plays a crucial role in immune responses and inflammation regulation. Elevated levels of IL-6 are associated with various inflammatory diseases and conditions, making it a significant therapeutic target: https://lnkd.in/gRRkFsVZ
-
